Zymeworks share price logo

Zymeworks

NASDAQ: ZYME

Mid Cap

$29.19

-0.71

(-2.37%)

as on

Zymeworks Stock Performance

as on September 5, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $29.11
    $29.99
    downward going graph

    0.27%

    Downside

    2.74%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $14.06
    $31.34
    downward going graph

    51.85%

    Downside

    7.37%

    Upside

    downward going graph

Zymeworks share price movements today

Previous Close
$29.90
Open
$29.81
Volume
451.6K
Market Cap
$2.2B
Day's Low - High
$29.11 - $29.99
52 Week Low - High
$14.06 - $31.34

Zymeworks Historical Returns

1 Month Return
+ 31.2 %
3 Month Return
+ 19.12 %
1 Year Return
+ 112.36 %
3 Year Return
+ 299.2 %
5 Year Return
-7.91 %

Zymeworks Stock Fundamentals & Key Indicators

Check Zymeworks market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.2B

EPS (TTM)

-2.02

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-12.75

Industry PE ratio

-13.53

PEG Ratio

0.1851922274066829

EBITDA

-139.9M

Revenue (TTM)

37.1M

Profit Margin

87.78%

Return On Equity TTM

-0.74%

Zymeworks Stock Valuation

Track how Zymeworks P/E has moved over time to understand its valuation trends.

Zymeworks in the last 5 years

  • Overview

  • Trends

Lowest (-24.38x)

December 31, 2025

Today (-24.38x)

December 31, 2025

Industry (-13.53x)

December 31, 2025

Highest (4.12x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -24.38x

Zymeworks vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Zymeworks with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$2.2B-7.91%-12.7587.78%NA
BUY$44.6B614.61%NA0.00%NA
BUY$141.1B181.73%32.2186.04%NA
BUY$60.2B-64.27%-18.66-12.57%NA
BUY$84.8B24.12%20.1484.86%0.44%

Stock Returns calculator for Zymeworks Stock including INR - Dollar returns

The Zymeworks stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Zymeworks investment value today

Current value as on today

₹2,22,134

Returns

₹1,22,134

(+122.13%)

Returns from Zymeworks Stock

₹1,07,315 (+107.32%)

Dollar Impact

₹14,819 (+14.82%)

Analyst Recommendation on Zymeworks Stock

Based on 10 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 10 analysts, 100% of analysts recommend a 'BUY' rating for Zymeworks. Average target price of $41.58

Zymeworks Share Price Target

Get share price movements and forecasts by analysts on Zymeworks.

What analysts predicted

29.8%UPSIDE

Target Price

$41.58

Current Price

$29.19

Analyzed by

10 Analysts

Target

$41.58

Zymeworks target price $41.58, a slight upside of 29.8% compared to current price of $29.19. According to 10 analysts rating.

Indian Investors' Interest in Zymeworks Stock

Search interest for Zymeworks Stock has increased by 544% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:544% versus previous 30 day period

Zymeworks Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
10
19
16
31
27
48
27
2
2
4
Gross Profit
10
19
16
31
27
48
27
0
0
4
Operating Income
-37
-42
-34
-22
-25
0
-22
-44
-47
-42
EBITDA
-20
-23
-31
-18
-22
2
-15
-39
-41
-43
Interest Expense
-
-
-
-
-
-
-
-
2
-
Depreciation
2
2
2
3
3
3
2
1
2
2
Income Before Tax
-31
-37
-29
-17
-22
2
-18
-41
-46
-45
Income Tax Expense
0
0
0
5
0
0
1
0
-2
0
Net Income
-31
-37
-29
-23
-22
2
-19
-41
-44
-45
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
32.76%
-18.23%
100.00%

Zymeworks Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
51
53
29
38
26
412
76
76
105
Gross Profit
10
-3
-87
-131
26
412
-66
76
105
Operating Income
-8
-33
-151
-187
-215
130
-138
-137
-92
EBITDA
-6
-30
-148
-183
-206
142
-120
-108
-68
Interest Expense
1
0
-
-
-
-
-
-
-
Depreciation
2
3
2
3
9
12
17
11
11
Income Before Tax
-9
-34
-144
-180
-212
135
-119
-116
-79
Income Tax Expense
0
2
0
0
0
10
0
6
1
Net Income
-10
-36
-145
-180
-211
124
-118
-122
-81
Net Profit Margin
20.51%
-7.37%
-296.34%
-338.75%
100.00%
100.00%
-88.11%
100.00%
100.00%

Zymeworks Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-31
-37
-29
-23
-22
2
-19
-41
-44
-45
Operating Cash Flow
-37
-24
-5
-41
-3
12
-31
-9
-45
-31
Investing Cash Flow
-7
-19
72
-6
12
8
0
5
69
17
Financing Cash Flow
2
1
-14
-8
1
1
-2
-18
178
-50
Change in Cash
-42
-43
51
-56
10
22
-33
-23
203
-64

Zymeworks Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-10
-36
-145
-180
-211
124
-118
-122
-81
Operating Cash Flow
0
24
-81
-151
-192
144
-118
-110
-33
Investing Cash Flow
-30
-109
-25
-43
144
-53
-207
38
26
Financing Cash Flow
49
91
193
308
8
108
81
-20
-18
Change in Cash
19
6
86
113
-40
199
-243
-91
-24

Mutual Funds that own Zymeworks Stock

Check out the Mutual Funds with significant holdings in Zymeworks.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
2.327128%
1651313
TIAA-CREF Funds
0.910684%
646215
Fidelity Securities Fund
0.779532%
553150
DFA INVESTMENT DIMENSIONS GROUP INC
0.756927%
537110
Fidelity Salem Street Trust
0.74753%
530442

Global Institutional Holdings in Zymeworks

Funds
Holdings
Joseph Edelman
5.89%
iShares
3.55%
Vanguard
2.78%
Stephen A. Schwarzman
2.28%
Xtrackers
1.96%

Zymeworks News & Key Events

  • img

    Today's Timeline - 29 June

    Mon, 04:03 PM

    -

    Zymeworks agrees to acquire Theravance Biopharma for $929 million, enhancing its commercial portfolio and revenue sources.

Insights on Zymeworks

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 2.40M → 4.59M (in $), with an average increase of 47.5% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ZYME has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, ZYME stock has moved up by 24.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 479.0% return, outperforming this stock by 385.0%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 5 quarters, 2.31M → -45.01M (in $), with an average decrease of 266.3% per quarter

About Zymeworks

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
OrganisationZymeworks
Headquarters108 Patriot Drive, Middletown, DE, United States, 19709
IndustryBiotechnology
CEOMr. Kenneth H. Galbraith C.A.
E-voting on sharesClick here to vote

Key Management of Zymeworks

Name

Title

Ms. Kristin Stafford CPA

Executive VP & CFO

Mr. Mark Hollywood

Executive VP & COO

Mr. Paul R. Schneider

Executive VP & General Counsel

Ms. Diana Papove B.Com.

Vice President of Corporate Communications

Dr. Lindsey Foulkes B.Sc., Ph.D.

Senior Vice President of Corporate Development & Strategy

Ms. Laura O'Connor

Senior VP & Chief Human Resources Officer

Dr. Paul A. Moore Ph.D.

Chief Scientific Officer

Mr. Scott Platshon B.S.

Executive VP & Chief Business Officer

Mr. Kenneth H. Galbraith C.A.

Chairman of the Board, CEO & President

Ms. Shrinal Inamdar B.Sc.

Vice President of Investor Relations

FAQs

What is Zymeworks share price today?

Zymeworks share price today is $29.19 as on at the close of the market. Zymeworks share today touched a day high of $29.99 and a low of $29.11.

What is the 52 week high and 52 week low for Zymeworks share?

Zymeworks share touched a 52 week high of $31.34 on and a 52 week low of $14.06 on . Zymeworks stock price today i.e. is closed at $29.19,which is 6.86% down from its 52 week high and 107.68% up from its 52 week low.

What is Zymeworks's market capitalisation today?

Zymeworks market capitalisation is $0.00T as on .

How to invest in Zymeworks Stock (ZYME) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Zymeworks on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Zymeworks Shares that will get you 0.0514 shares as per Zymeworks share price of $29.19 per share as on September 5, 2026 at 8:46 am IST.

What is the minimum amount required to buy Zymeworks Stock (ZYME) from India?

Indian investors can start investing in Zymeworks (ZYME) shares with as little as ₹94.49 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹944.90 in Zymeworks stock (as per the Rupee-Dollar exchange rate as on ). Based on Zymeworks share’s latest price of $29.19 as on September 5, 2026 at 8:46 am IST, you will get 0.3426 shares of Zymeworks. Learn more about fractional shares .

What are the returns that Zymeworks has given to Indian investors in the last 5 years?

Zymeworks stock has given -7.91% share price returns and 29.96% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?